Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases

Abstract

Anti-tumour necrosis factor (TNF)-α agents have been increasingly used to treat patients affected by inflammatory bowel disease and dermatological and rheumatologic inflammatory disorders. However, the widening use of biologics is related to a new class of adverse events called paradoxical reactions. Its pathogenesis remains unclear, but it is suggested that cytokine remodulation in predisposed individuals can lead to the inflammatory process. Here, we dissect the clinical aspects and overall outcomes of autoimmune diseases caused by anti-TNF-α therapies.

Keywords

• infliximab
• adalimumab
• etanercept
• certolizumab pegol
• golimumab
• autoimmune diseases